Charles Ray, MD
Urology · Lexington, KYNPI 1356348429
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 187 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,801, 3.0 times the $610 reported in 2019.
Across 187 payments — averaging $26.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$606
- Sumitomo Pharma America, Inc.$557
- Astellas Pharma US Inc$545
- AbbVie$393
- Medtronic$312
- Pfizer$304
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,69196%
- Education$1794%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 9 | $606 |
| Sumitomo Pharma America, Inc. | 22 | $557 |
| Astellas Pharma US Inc | 27 | $545 |
| AbbVie(2 entities) | 21 | $393 |
| Medtronic | 12 | $312 |
| Pfizer | 17 | $304 |
| Axonics, Inc. | 6 | $236 |
| Antares Pharma, Inc. | 9 | $202 |
| Telix Pharmaceuticals | 3 | $178 |
| Johnson & Johnson(2 entities) | 10 | $171 |
| Accord Healthcare, Inc. | 7 | $154 |
| Neotract Inc. | 1 | $150 |
| Bayer | 1 | $125 |
| Urogen Pharma, Inc. | 4 | $88 |
| Ferring Pharmaceuticals Inc. | 4 | $81 |
| Calyxo, Inc. | 1 | $75 |
| Novartis | 3 | $72 |
| Sun Pharmaceutical Industries Inc. | 3 | $64 |
| Halozyme Inc | 2 | $57 |
| Endo USA, Inc. | 2 | $50 |
| Verity Pharmaceuticals Inc. | 2 | $49 |
| 180 Medical, Inc. | 2 | $47 |
| Blue Earth Diagnostics | 2 | $46 |
| Myovant Sciences Inc. | 2 | $43 |
| Endo Pharmaceuticals Inc. | 3 | $43 |
| Urovant Sciences Inc | 2 | $41 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $25 |
| Ambu Inc. | 1 | $22 |
| Cycle Pharmaceuticals Inc | 1 | $20 |
| Innovation Technologies Inc | 1 | $18 |
| Agiliti Surgical, Inc. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Coloplast | 1 | $16 |
| Dentsply IH Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ILLUCCIX$285
- UroLift$150
- GENERAL KIDNEY STONE DISEASE$149
- Axonics$146
- Lumenis Pulse 120H$140
- LithoVue$134
- Kerendia$125
How this compares
$4,870 in reported general payments places this provider in the 65th percentile of 139 urology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 24 | $336,431 |
| ErleadaApalutamide | 12 | $181,458 |
| MyrbetriqMirabegron | 58 | $40,674 |
| Tamsulosin Hcl | 524 | $6,739 |
| GemtesaVibegron | 12 | $6,628 |
| Methenamine Hippurate | 77 | $5,017 |
| Oxybutynin Chloride ErOxybutynin Chloride | 205 | $4,913 |
| Dutasteride | 101 | $3,203 |
| NitrofurantoinNitrofurantoin Macrocrystal | 121 | $2,937 |
| Tolterodine Tartrate ErTolterodine Tartrate | 19 | $2,801 |
| Testosterone Cypionate | 64 | $2,696 |
| Estradiol | 36 | $2,478 |
| Potassium Citrate ErPotassium Citrate | 43 | $2,359 |
| Finasteride | 155 | $2,066 |
| Bicalutamide | 44 | $1,471 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $545 | $377,10582 claims |
| Johnson & JohnsonErleada | $171 | $181,45812 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $557 | $6,62812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 139 urology providers in Kentucky.
Other urology in Lexington
- Thomas SlabaughLexington$102K
- Patrick HensleyLexington$50K
- Stephen MonnigLexington$18K
- Frances MartinLexington$11K
- Andrew ToddLexington$9K
- Terrence GrimmLexington$9K
- Andrew HarrisLexington$8K
- James AngelLexington$8K
- Justin JohnsonLexington$7K
- Fred HadleyLexington$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.